Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aytu BioScience Inc.

aytubio.com

Latest From Aytu BioScience Inc.

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Pipeline Watch: Three Approvals, Five Filings And One Launch

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Research & Development Pipeline Watch
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Biosensors
    • Chemistry, Immunoassay
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Rosewind Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Aytu BioScience Inc.
  • Senior Management
  • Josh Disbrow, CEO
    David Green, CFO
    Jarrett Disbrow, COO
  • Contact Info
  • Aytu BioScience Inc.
    Phone: (855) 298-8246
    373 Inverness Pkwy.
    Ste. 206
    Englewood, CO 80112
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register